Open Access. Powered by Scholars. Published by Universities.®
Social and Behavioral Sciences Commons™
Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 6 of 6
Full-Text Articles in Social and Behavioral Sciences
Metabotropic Glutamate Receptor Subtype 5 Is Reduced In Schizophrenia Subjects With Comorbid Major Depression And Unchanged Following Antipsychotic Drug Treatment, N Jimenez, Xu-Feng Huang, C Deng, K Newell
Metabotropic Glutamate Receptor Subtype 5 Is Reduced In Schizophrenia Subjects With Comorbid Major Depression And Unchanged Following Antipsychotic Drug Treatment, N Jimenez, Xu-Feng Huang, C Deng, K Newell
Xu-Feng Huang
Abstract of a paper that presented at the Australian Neuroscience Society 32nd Annual meeting.
Neuregulin-1 Signalling And Antipsychotic Treatment: Potential Therapeutic Targets In A Schizophrenia Candidate Signalling Pathway, Chao Deng, Bo Pan, Martin Engel, Xu-Feng Huang
Neuregulin-1 Signalling And Antipsychotic Treatment: Potential Therapeutic Targets In A Schizophrenia Candidate Signalling Pathway, Chao Deng, Bo Pan, Martin Engel, Xu-Feng Huang
Xu-Feng Huang
Identifying the signalling pathways underlying the pathophysiology of schizophrenia is an essential step in the rational development of new antipsychotic drugs for this devastating disease. Evidence from genetic, transgenic and post-mortem studies have strongly supported neuregulin-1 (NRG1)-ErbB4 signalling as a schizophrenia susceptibility pathway. NRG1-ErbB4 signalling plays crucial roles in regulating neurodevelopment and neurotransmission, with implications for the pathophysiology of schizophrenia. Post-mortem studies have demonstrated altered NRG1-ErbB4 signalling in the brain of schizophrenia patients. Antipsychotic drugs have different effects on NRG1-ErbB4 signalling depending on treatment duration. Abnormal behaviours relevant to certain features of schizophrenia are displayed in NRG1/ErbB4 knockout mice or …
Structural Contributions Of Antipsychotic Drugs To Their Therapeutic Profiles And Metabolic Side Effects, Somayeh Jafari, Francesca Fernandez-Enright, Xu-Feng Huang
Structural Contributions Of Antipsychotic Drugs To Their Therapeutic Profiles And Metabolic Side Effects, Somayeh Jafari, Francesca Fernandez-Enright, Xu-Feng Huang
Xu-Feng Huang
Antipsychotic drugs have various neuropharmacological properties as a result of their structural diversity. Despite their therapeutic benefits, most of the prescribed atypical antipsychotics can induce severe side effects, including weight gain, type II diabetes mellitus, and cardiovascular diseases. Among the developed atypical antipsychotic agents, tetracyclic dibenzodiazepine and thienobenzodiazepine compounds, particularly clozapine and olanzapine, are associated with the greatest weight gain and metabolic disturbances. However, the unique chemical structure of these compounds causes the low risk of side effects reported for typical antipsychotics (e.g. extrapyramidal symptoms and tardive dyskinesia). This report reviews the recent discovery of the potential role of the …
Short- And Long-Term Effects Of Antipsychotic Drug Treatment On Weight Gain And H1 Receptor Expression, Kelly Newell, Xu-Feng Huang, Chao Deng, Tom Burne, Mei Han
Short- And Long-Term Effects Of Antipsychotic Drug Treatment On Weight Gain And H1 Receptor Expression, Kelly Newell, Xu-Feng Huang, Chao Deng, Tom Burne, Mei Han
Xu-Feng Huang
The present study investigated body weight gain, food intake, open-field activity and brain histamine H1 receptor mRNA and protein expression in rats treated with three types of antipsychotics. Rats were divided into eight groups and treated with aripiprazole (2.25mg/kg/day), olanzapine (1.5mg/kg/day), haloperidol (0.3mg/kg/day) or vehicle (as control) for 1 or 12 weeks. Administration of olanzapine for 1 week led to a threefold increase in body weight gain and a 35% increase in fat deposits compared to controls (p<0.05). In the 12-week olanzapine treatment group, accumulative food intake was significantly higher in the first 7 weeks of treatment compared to …
Effects Of Antipsychotic Medication On Muscarinic M1 Receptor Mrna Expression In The Rat Brain, Kelly Newell, Xu-Feng Huang, Katerina Zavitsanou, Chao Deng, Mei Han
Effects Of Antipsychotic Medication On Muscarinic M1 Receptor Mrna Expression In The Rat Brain, Kelly Newell, Xu-Feng Huang, Katerina Zavitsanou, Chao Deng, Mei Han
Xu-Feng Huang
Alterations in muscarinic M1 receptor protein and mRNA expression have been revealed in post-mortem brains of schizophrenia patients. Most patients had been treated with antipsychotics, so medication effects cannot be excluded as a possible explanation for these results. With in situ hybridization, this study investigated M1 receptor mRNA expression in rats treated with the typical antipsychotic haloperidol (0.3 mg/kg/day) and the atypical antipsychotics olanzapine (1.5 mg/kg/day) and aripiprazole (2.25 mg/kg/day) for 1 or 12 weeks. Compared with the control group, haloperidol significantly increased (13-21%, P < 0.05) M1 mRNA expression in the CA1, CA2, and CA3 regions of the hippocampus after both 1 and 12 weeks of treatment, and it also increased (17%, P < 0.01) M1 mRNA expression in the substantia nigra compacta after 1 week of treatment. Olanzapine significantly increased (14-22%, P < 0.05) M1 mRNA expression in the hippocampus (CA1, CA2, and CA3) and substantia nigra compacta after 12 weeks of treatment, but not after 1 week. Aripiprazole significantly increased (17%, P < 0.01) M1 mRNA expression in the hippocampus (CA1) after both 1 and 12 week treatments and increased (12%, P < 0.05) M1 mRNA expression in the nucleus accumbens after 1 week of treatment. Despite their different affinities for muscarinic M1 receptors, all three antipsychotic medications induced a similar trend of change in M1 mRNA expression in selected brain regions. These data suggest that the decreased M1 receptor protein and mRNA expression observed in schizophrenia patients is unlikely to be a consequence of drug treatments and implicates muscarinic M1 receptors in the pharmacotherapy of the disease. ÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂÃÂé 2007 Wiley-Liss, Inc.
Effects Of Typical And Atypical Antipsychotic Drugs On Rat Brain Muscarinic Receptors, Van Nguyen, Xu-Feng Huang, Katerina Zavitsanou, Mei Han
Effects Of Typical And Atypical Antipsychotic Drugs On Rat Brain Muscarinic Receptors, Van Nguyen, Xu-Feng Huang, Katerina Zavitsanou, Mei Han
Xu-Feng Huang
No abstract provided.